Tribune Therapeutics is a pre-clinical stage biopharmaceutical company developing novel biological drugs to treat patients with fibrotic diseases, including diseases affecting the kidney, lung and liver. Based on research from Håvard Attramadal‘s lab at Oslo University Hospital, Tribune’s medicines target the CCN protein family. The CCN protein family is a group of signalling proteins central […]

View post to subscribe to site newsletter.

xFOREST Therapeutics is a Japanese startup developing a platform for targeting disease-related RNA structures with small molecules. The company’s platform enables the search for highly specific RNA-binders, empowering the rapid and efficient discovery of RNA-targeting drugs. Tens of thousands of RNAs and tens of thousands of compounds from libraries can be analyzed in parallel with […]

View post to subscribe to site newsletter.

Angios is developing new treatments for challenging vascular diseases using the vascular organoid model developed by the company’s founders. The vascular organoids allow the company to model human microvascular complications in the dish and thereby find new pathways associated with disease progression. Diseases affecting blood vessel functionality remain an unresolved global health problem, especially in […]

View post to subscribe to site newsletter.